Research and Data Analytics Sample Clauses

Research and Data Analytics. The Contractor shall provide research and data analytics to support the 2020 Census Integrated Communications Contract. The Contractor shall review and validate existing research, conduct additional research, and analyze data to support the overall program. The Contractor shall base the strategies and tactics of the communications program on a solid research foundation. In sum, the Contractor shall research all elements of the program across all audiences to ensure that the communications resonate with the targeted audiences based on the final communications plan that is developed after award. The creative strategies and promotional materials shall be based on validated communications strategies, ensuring that the overall intended messages are clear, compelling, persuasive, and most importantly, culturally relevant and sensitive. The Contractor and all subcontractors conducting research shall comply with the Office of Management and Budget (OMB) regulations regarding surveys and research. See link provided in Section G.4 for information on the Paperwork Reduction Act and Information Collections Policy. Examples of research work may include, but is not limited to: • Overall research plan/roadmap • Audience segmentation research • Predictive household or person level model • Copy testing • Digital usability testing • A/B testing • Historical trend analysis of attitudes • Research on emerging communications technologies and channels The Contractor shall collect and analyze a wide variety of state of the art metrics and data analytics to monitor and track the program over its lifecycle. The Contractor shall conduct on- going situational analysis to stay abreast of any changes such as political and environmental influences that could negatively impact participation rates. The Contractor shall monitor and track participation rates throughout the country. The Contractor shall collect real-time data that enables the Census Bureau to make on-the-fly changes in message content and media approach to gain the desired communications among key target audience segments and geographic areas. The Contractor shall ensure that through data analytics, the Census Bureau has a nimble and fluid program that can rapidly and decisively respond to marketplace developments with the potential to affect and improve participation. Examples of data analytics work may include, but is not limited to: • Real-time tracking and monitoring study • Real-time reporting of response rates • Commu...
View SourceView Similar (2)
Research and Data Analytics 
View SourceView Similar (2)

Related to Research and Data Analytics

  • Technology Research Analyst Job# 1810 General Characteristics

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Laboratory Services Covered Services include prescribed diagnostic clinical and anatomic pathological laboratory services and materials when authorized by a Member's PCP and HPN’s Managed Care Program.

  • Analytics 1.1. IFS may track and analyze the usage of the IFS Offering for purposes of determining usage made of the IFS Offering, for the purposes of security, to assist customers, and for improving the Software and Services and the user experience in using such Software and Services. For example, IFS may use this information to help customers derive more value from the Software and Services, to understand and analyze trends, or to track which features are used most often in order to improve the Software and Services. IFS may share anonymous usage data with its service providers for the purpose of helping in such tracking, analysis and improvements. Additionally, IFS may share such anonymous usage data on an aggregate basis in the normal course of operating their business; for example, IFS may share information publicly to show trends about the general use of its software and services. TERMS - SERVICES

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.